Allergy Therapeutics publishes positive Phase III data for Grass MATA MPL

CSL's ANDEMBRY receives European approval to prevent attacks of hereditary angioedema

NICE recommends ALK's ACARIZAX for house dust mite allergic rhinitis treatment in UK's NHS

European Commission approves Palforzia for toddlers with peanut allergy

Eli Lilly and Co receives approval from FDA for Zepbound

CSL gains EMA backing for Garadacimab as HAE prophylactic treatment

Merck initiates Phase 3 trial for LAGEVRIO (molnupiravir)

Allergy Therapeutics reports positive data from VLP Peanut PROTECT trial

CBC Group acquires UCB's mature neurology and allergy business in China

Allergy Therapeutics begins Phase III trial for grass allergy treatment in children

Allergy Therapeutics announces Marketing Authorisation Application submission for Grass MATA MPL in Germany

Biopharmaceutical company BioVaxys partner SpayVac for Wildlife scales up vaccine production in Madison facility

IgGenix doses first patient in IGNX001 ACCELERATE Peanut Phase 1 trial

ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices

IgGenix presents IGNX001 data at 2024 ASCIA